<DOC>
	<DOCNO>NCT01392794</DOCNO>
	<brief_summary>A study compare time-course change plasma concentration YM060 intake conventional tablet orally-disintegrating tablet . Orally-disintegrating tablet administer without water .</brief_summary>
	<brief_title>A Study Compare Oral Absorption YM060 Between Orally-disintegrating Tablet ( Without Water ) Conventional Tablet</brief_title>
	<detailed_description />
	<mesh_term>Ramosetron</mesh_term>
	<criteria>healthy assess principal investigator subinvestigators nonsmoking stop smoking least 90 day study body weight : 50.0kg less 80.0kg body mass index ( BMI ) : 17.6 less 26.4 participate another clinical trial ( include postmarketing clinical study ) within 120 day study donate 400mL whole blood within 90 day , 200mL whole blood within 30 day blood component within 14 day study receive drug within 7 day study go receive drug deviance normal range vital sign ( blood pressure , pulse rate , body temperature ) 12lead ECG deviance normal range labtests history drug allergy history current diagnosis stomach , small intestine large intestine diseases history current diagnosis inflammatory bowel disease ( Crohn 's disease colitis ulcerative ) history current diagnosis colitis ischemic history current diagnosis hepatic disease history current diagnosis cardiovascular disease history current diagnosis respiratory diseases history current diagnosis malignant tumor receive ramosetron tablet</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>YM060</keyword>
	<keyword>ramosetron</keyword>
	<keyword>orally-disintegrating tablet</keyword>
	<keyword>OD tablet</keyword>
	<keyword>bioequivalence</keyword>
</DOC>